| Unique ID issued by UMIN | UMIN000057176 |
|---|---|
| Receipt number | R000065343 |
| Scientific Title | Thrombus aspiration in acute coronary syndrome: Pathology and OCT Correlations |
| Date of disclosure of the study information | 2025/02/28 |
| Last modified on | 2025/02/28 16:47:45 |
Thrombus aspiration in acute coronary syndrome: Pathology and OCT Correlations
TAPOS
Thrombus aspiration in acute coronary syndrome: Pathology and OCT Correlations
TAPOS
| Japan | Europe |
Acute Coronary Syndrome (ACS)
| Cardiology |
Others
NO
OCT has clinically contributed to disclose the mechansm of acute coronary syndrome (ACS) including ruptured fibrous (RFC-ACS), plaque erosion (i.e. intact fibrous caps: IFC-ACS) or calcified nodule (CN-ACS). However, it has not yet been fully examined whether OCT findings coincide with in-vivo pathological analysis in ACS. To disclose the mechanism of ACS and role of macrophage phenotype, the investigators prosepectively performed OCT imaging and athero-thrombotic aspiration before PCI.
Safety,Efficacy
The primary endpoint is a composite of cardiovascular death, acute coronary syndrome (ACS), ischemia-driven revascularization, cardiogenic shock, and cardiac failure required hospital admission for 3 years.
Secondary endpoints are the individual components of the primary endpoints.
Observational
| 20 | years-old | < |
| 90 | years-old | >= |
Male and Female
(1) Aged >20 years, (2) a diagnosis of ACS, (3) native coronary artery lesions, (4) optical coherence tomography with sufficient quality before PCI, (5) successful thrombus aspiration with enough amount of thrombus. Recent guidelines and consensus documents indicated that routine thrombus aspiration is not recommended, but in cases of large residual thrombus burden, thrombus aspiration may be considered. Therefore, we performed athero-thrombotic aspiration only in patients who would have a merit of the aspiration procedure due to large thrombus burden.
(1) they have cardiogenic shock, (2) they have coronary bypass grafting (CABG), (3) they have contraindications to anticoagulation and anti-platelet therapy, (4) lesions located in tortuous vessels, in ostial segment, and in the left main stem are excluded from the study due to the difficulty in performing high-quality intracoronary imaging.
200
| 1st name | YUKIO |
| Middle name | |
| Last name | OZAKI |
Fujita Health University School of Medicine
Cardiology
461-0021
1-98 Dengaku, Kutsukake, Toyoake, Japan 470-1192
08030713131
yukio.ozaki7@gmail.com
| 1st name | YUKIO |
| Middle name | |
| Last name | OZAKI |
Fujita Health University School of Medicine
Cardiology
470-1192
1-98 Dengaku, Kutsukake, Toyoake, Japan 470-1192
+819015609030
yukio.ozaki7@gmail.com
Other
YUKIO OZAKI
Other
Self funding
JAPAN
Fujita Health University School of Medicine
1-98 Dengaku, Kutsukake, Toyoake, Japan 470-1192
08030713131
yukio.ozaki7@gmail.com
NO
| 2025 | Year | 02 | Month | 28 | Day |
Not yet
Unpublished
Not yet
200
| 2028 | Year | 12 | Month | 31 | Day |
Open public recruiting
| 2016 | Year | 01 | Month | 01 | Day |
| 2016 | Year | 07 | Month | 25 | Day |
| 2016 | Year | 07 | Month | 25 | Day |
| 2029 | Year | 12 | Month | 31 | Day |
| 2030 | Year | 12 | Month | 31 | Day |
Pathological analysis is performed independently without any information of clinical and OCT data at Centre for Inherited Cardiovascular Diseases, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy. The investigators compare OCT imaging analysis results, in-vivo pathological analysis results and clinical outcome without any interaction.
| 2025 | Year | 02 | Month | 28 | Day |
| 2025 | Year | 02 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000065343